Even amid a tech boom, there are deals prompted by declining valuations, revenue shortfalls and delayed product launches. Cooley’s Mehdi Khodadad faced such a situation with Paratek Pharmaceuticals, a Boston company that is developing an antibiotic for people with drug-resistant infections.
Paratek had planned to go public in 2012, but that offering was derailed, in part because of uncertainty surrounding its products. By 2014, the company was further along in the development and regulatory approval process but had an even greater need for cash.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
